John Leonard

John Leonard is a senior lymphoma oncologist who participated in the L-MIND trial establishing the CD19-directed antibody tafasitamab plus lenalidomide as a treatment for relapsed/refractory DLBCL ineligible for transplant, leading to FDA approval. He has contributed to multiple DLBCL trial designs including evaluations of adding novel agents to R-CHOP and optimization of frontline treatment. He chairs the ASH Lymphoma subcommittee and has mentored dozens of lymphoma fellows. His long career spans from the rituximab era to the current age of bispecifics and cellular therapy.